ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

J&J Provides Added Doxil Supply for Clinical Studies

By Peter Loftus Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer. Doxil has been in short supply since J&J's contract manufacturer experienced factory problems last year. Apart from affecting patients who were prescribed Doxil, the shortage also held up clinical trials of experimental drugs that were being tested with or against Doxil. J&J said Thursday it would provide supplies of Doxil to two clinical trials. One is a late-stage study testing whether Endocyte's EC145 and Doxil improves overall survival of women with ovarian cancer, versus Doxil alone. Endocyte said in a separate statement the additional Doxil would supplement an existing supply that was already in place to support the trial, and would allow the company to continue to enroll patients without interruption. Endocyte in April agreed to license EC145 to Merck & Co. (MRK), which gained global rights to develop and commercialize the drug in exchange for a $120 million up-front payment and up to $880 million in additional payments if certain milestones are met. Endocyte retains the right to co-promote the drug with Merck in the U.S. In addition, J&J will supply Doxil to be used in a clinical trial of VentiRx Pharmaceuticals' experimental cancer drug VTX-2337. J&J said its Doxil supplier, Boehringer Ingelheim's Ben Venue Laboratories unit, is making progress toward resuming production of Doxil near the end of this year. Ben Venue suspended production late last year as it tried to fix manufacturing problems identified by drug regulators. J&J has been allocating remaining supplies of Doxil through a rationing program. Earlier this year, the Food and Drug Administration approved the temporary importation of a replacement drug for Doxil, known as Lipodox. J&J said it will continue to pursue a shorter-term option to begin restoring Doxil supplies before the end of the year. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
02/11/201613:59:19Schedule 13g<br /> (sc 13g/a)
02/10/201613:34:00Correction to Merck & Co. Article on Jan. 15
02/10/201610:28:27Amended Statement of Ownership (sc 13g/a)
02/10/201608:50:59Amended Statement of Ownership (sc 13g/a)
02/04/201608:00:00FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) fo...
02/03/201616:13:00Merck Posts Lower Revenue and Profit -- 2nd Update
02/03/201616:09:00Correction to Merck Earnings Story
02/03/201613:08:00Merck Revenue and Profit Falls -- Update
02/03/201608:30:00Merck Revenue and Profit Falls
02/03/201608:21:00Merck Revenue and Profit Falls
02/03/201606:57:37Current Report Filing (8-k)
02/03/201606:45:00Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
01/28/201621:36:00FDA Approves Merck's New Hepatitis C Treatment -- 2nd Update
01/28/201620:15:00FDA Approves Merck's New Hepatitis C Treatment -- Update
01/28/201619:10:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) f...
01/28/201618:59:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir & grazoprevir) f...
01/27/201613:49:00FDA to Review Merck Antitoxin for Clostridium Difficile
01/27/201608:30:00Merck Announces FDA Acceptance of Biologics License Application...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad